Abstract. Antibody-drug conjugates (ADCs) are emerging modalities in the pharmaceutical industry. Characterization of ADC's drug-to-antibody ratio (DAR) becomes a key assessment because of its importance in ADC efficacy and safety. DAR characterization by conventional intact protein MS analysis, however, is challenging because of high heterogeneity of ADC samples. The analysis often requires protein deglycosylation, disulfide-bond reduction, or partial fragmentation. In this study, we illustrate the practical utility of ion mobility mass spectrometry (IM-MS) in a routine LC/ MS workflow for DAR measurements. This strategy allows analyte Bcleanup^in the gas phase, providing significant improvement of signal-to-noise ratios of ADC intact mass spectra for accurate DAR measurements. In addition, protein drift time analysis offers a new dimension in monitoring the changes of DAR in lot-to-lot analysis.
Introduction
M onoclonal antibodies (mAbs) have been acknowledged as powerful therapeutic agents because of their high specificity and affinity for target binding [1] . For the past three decades, the market for therapeutic mAbs has grown exponentially since the first therapeutic mAb reached the market in the mid-1980s [2] . Based on the unique features of mAbs, conjugation of cytotoxic drugs to mAbs, namely antibody-drug conjugates (ADCs), expands their therapeutic applications on cancer therapy with significant improvement of efficacy and safety compared with traditional chemotherapeutic drugs. To date, three ADCs, gemtuzumab ozogamicin (Mylotarg), adotrastuzumab emtansine (Kadcyla), and brentuximab vedotin (Adcetris), have been approved in the US, and more ADCs are at various stages of development [1] .
The efficacy of ADCs is directly correlated to the amount and stability of conjugated drug. Therefore, characterization of drug-to-antibody ratio (DAR) is an essential assessment in both discovery and development processes for ADCs evaluation. There are three types of ADCs based on different drug conjugation methods: inter-chain cysteine-conjugated ADCs, lysineconjugated ADCs, and artificial site-specific conjugated ADCs [1] . Different types of conjugation methods produce different levels of heterogeneity, resulting in the complexity in DAR characterization. Several strategies have been implemented in routine DAR measurements, including LC/UV analysis [3] , hydrophobic interaction chromatography (HIC) column separation [3, 4] , capillary iso-electric focusing (cIEF) analysis [5] , and intact MS analysis of ADCs [3, 6, 7] . However, each methodology has its own limitations in terms of resolution and sensitivity. The most challenging DAR characterization is for random lysine-conjugated ADCs, which have extremely high levels of heterogeneity attributable to drug conjugation, glycosylation, and incomplete drug conjugation. Strategies such as protein fragmentation and protein deglycosylation have been developed to reduce the heterogeneity. In the protein fragmentation method, ADCs are fragmented by disulfide- bond reduction or mAb hinge region cleavage to produce smaller protein pieces, resulting in better resolution during instrumental analysis [6] . This method is time-consuming because of multipledata processing for all fragments and limited in practical applications. Utility of deglycosylation in DAR characterization is a standard method. However, it introduces deglycosidase [e.g., peptide-N-glycosidase F (PNGaseF)] into the sample, which is difficult to be separated from intact ADCs using reversed-phase chromatography and could suppress the analytical signals of ADCs.
In this report, we demonstrate the implementation of ion mobility into standard reversed-phase LC/MS workflow for DAR measurements at the intact protein level. Ion mobility mass spectrometry (IM-MS) allows separation of different sizes/shapes of ions in the gas phase. It provides a wide range of applications, including understanding the assembly of protein complexes [8] [9] [10] , the conformational characterizations of therapeutic proteins [11, 12] , cyclic peptides [13] , and metalbinding proteins [14] . The unique property of ion-size separation in an inert buffer gas by ion mobility has been illustrated in a hydrogen/deuterium exchange mass spectrometry (HDX-MS) study to separate the co-eluting peptides for ion signal improvement [15] . Recently, IM-MS has been coupled with HIC/MS for ADC's DAR measurements under protein-native condition and showed comparable results for DARs obtained by different methodologies [16] . In our study, we observed that the addition of ion mobility in routine reversed-phase LC/MS workflow for ADC analysis results in excellent separation of protein mixtures (e.g., deglycosidase and ADC) in the gas phase, providing improved signals of ADC ion cluster when conducting ADC deglycosylation. The ion mobility results also provide orthogonal information regarding the DAR changes in sample-to-sample comparison. This enhanced workflow significantly reduces the complexity of DAR characterization.
Experimental
An IgG1 mAb, its corresponding site-specific ADC, and a random lysine-conjugated IgG1 ADC generated in-house, with a payload/linker of molecular weight 1309 Da, were prepared in PBS buffer, pH 7.4, and analyzed by liquid chromatography/ mass spectrometry (LC/MS) and LC/IM-MS. Deglycosylated ADCs were prepared by adding 1 μL of PNGaseF (500 U; New England Biolabs, Ipswich, MA, USA) into 10 μg of ADCs and the deglycosylation was performed at 37°C overnight. Sample with 1 μg of ADC was injected into an ACQUITY UPLC system (Waters Manchester, UK). Proteins were eluted from a Waters BEH C4 column (2.1 × 150 mm, 300 Å, 1.7 μm), heated at 60°C, using a 20 min LC gradient. The gradient setting was 10% to 38% solvent B in 10 min at 0.2 mL/min flow rate. Solvent A was 0.1% FA in water and solvent B was 0.1% FA in acetonitrile. Protein eluent was analyzed on a Waters Synapt G2 HDMS (Waters Manchester, UK) operated under sensitivity mode with ESI voltage at 3.5 kV, cone voltage at 35 V, and source temperature at 120°C. The mass spectrometer was precalibrated using sodium iodide, and [Glu1]-fibrinopeptide B was used for lock mass during each run.
The LC/IM-MS experiments were performed on a Waters Synapt G2 HDMS (Waters). The ion mobility settings were Pi = 3 mbar, Trap Bias = 45 V, Trap CE = 2 V, Phe = 180 mL/min, PN2 = 90 mL/min, IMS WV = 923 m/s, and IMS WH = 40 V. IM-MS measurements were performed in triplicate under identical IM parameters. Data interpretation was performed using MassLynx 4.1 and Driftscope 2.1 (Waters). The average DAR for each sample was calculated based on deconvoluted mass spectrum peak intensity as follows: DAR = Σ (deconvoluted peak intensity × number of loaded drugs) / Σ (deconvoluted peak intensity). Standard errors correspond to triplicate injections.
Results and Discussion
To perform DAR measurements of ADCs, especially random lysine-conjugated ADCs, one can deglycosylate the mAbs to reduce the heterogeneity from N-linked glycans in order to obtain more acceptable resolution of the intact payload distribution. The ion current of intact ADCs, however, could be significantly suppressed by the presence of co-eluting deglycosidase, PNGaseF, in a typical LC/MS experiment (Figure 1a) , affecting the quality of DAR measurements. Although PNGaseF can be removed off-line by molecular weight cut-off devices, this strategy is time consuming and could induce ADC sample loss during the procedure. To achieve a better separation of ADCs from PNGaseF in a standard LC/MS workflow, reversed-phase column with smaller pore size or the replacement of formic acid (FA) with trifluoroacetic acid (TFA) in the HPLC solvents can be applied. However, the use of smaller pore size column can lead to poor elution of ADC molecule and reduction of column life time [17] . Utility of TFA is not preferred because of the formation of protein-TFA adducts and ion signal suppression [18] . Another method such as on-line size exclusion chromatography (SEC)-MS [19] is relatively straightforward and could be used to separate PNGaseF from ADCs. In this study, we observed the potential of ion mobility in the standard reversed-phase LC/MS workflow, other than SEC-MS, to separate PNGaseF/ADCs mixtures. As illustrated in Figure 1b , compared with LC/MS workflow, LC/IM-MS with the same LC settings resulted in a similar LC chromatographic profile with a good separation of ADC ion cluster from that of PNGaseF in the ion mobiligram. Interestingly, we observed that LC/IM-MS provided a better separation of PNGaseF/ADC mixture than traditional SEC-MS (Supplemental Figure 1) using salt-free mobile phase system. The separation provided by LC/IM-MS significantly improved the signal-to-noise ratio (S/N) of ADC main mass spectral peak, leading to better resolved ADC deconvoluted mass spectrum. We applied this new approach to an unconjugated mAb, Figure 2 . The S/N of the most abundant peak (53 + ) measured for a mAb, a site-specific ADC (ADC-ss), and a random conjugated ADC (ADC-rc), before (black) and after (gray) the application of ion mobility. All molecules showed at least a 10× increment of S/N with LC/IM/MS workflow. The reported S/N is the average value of triplicate injections Another advantage for the use of ion mobility in ADC characterization is that the mobiligraphic separation can provide complementary information of DAR value to that measured by intact protein MS as shown in a recent study by Debaene et al. [16] using a native protein IM-MS workflow. Although the DAR calculation based on IM-MS results is not as straightforward as using traditional MS data, the overall drift time of ADC species obtained from IM-MS analysis allows DAR comparison in a rapid manner. As exhibited in Figure 3 , we artificially mixed an in-house mAb with its corresponding site-specific ADC at different ratios to generate samples with different DARs at 0, 0.3, 1.6, and 2 as determined by MS. We observed an increment of drift time for samples with increasing DARs. Given that antibodies were denatured under LC/IM-MS conditions, the change of ADC drift time was likely caused by the overall change of ADC ion size attributable to drug attachment. The changes of ADC drift time were significant when the DAR difference was greater than one, and the measurements were reproducible with <0.05 ms variations across triplicate injections. The measured ADC drift time in a given LC/IM-MS workflow could be used as a fingerprint for direct DAR comparison. To further test the robustness of this application, we evaluated a total of six lots of site-specific ADC with two different DARs (Figure 4 ). Four lots of ADC, with an average DAR of 1.9 ± 0.1 as determined by MS, showed an average IM drift time of 7.78 ± 0.01 with good precision. The other two lots of ADC, with an average DAR of 0.4 ± 0.1, also showed good precision in IM drift time of 7.67 ± 0.02. The drift time difference between these two groups of ADCs is statistically significant (P = 0.01), indicating the potential utility of LC/IM-MS in ADCs lot-to-lot comparison analysis.
In summary, we have illustrated that ion mobility can be implemented in a standard LC/MS workflow to facilitate ADC DAR characterization. The IM separation of protein mixtures significantly improves ADC protein MS signals. Drift-time measurements of ADCs provide complementary information for sample-to-sample DAR comparisons.
